Isomyosamine - TNF Pharmaceuticals
Alternative Names: MYMD-1Latest Information Update: 29 Oct 2025
At a glance
- Originator MyMD Pharmaceuticals
- Developer TNF Pharmaceuticals
- Class Alkaloids; Anti-inflammatories; Antirheumatics; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Rheumatoid arthritis; Sarcopenia
- Phase I Autoimmune disorders; Thyroiditis
Most Recent Events
- 13 Oct 2025 Phase I development in Autoimmune disorders is ongoing in USA (TNF Pharmaceuticals pipeline, October 2025)
- 13 Oct 2025 Phase-II clinical trials in Rheumatoid arthritis in USA (PO) prior to October 2025 (TNF Pharmaceuticals pipeline, October 2025)
- 24 Jun 2025 TNF Pharmaceuticals plans a compassionate use (expanded access) trial for Adenosine-deaminase-deficiency